Apigenin (4′,5,7-trihydroxyflavone) is a plant flavonoid found in chamomile flowers, parsley, celery seed, and many other botanicals. It has attracted growing consumer interest over the past few years, largely because it sits at the intersection of three active research areas: sleep and anxiety, where its molecular target is the GABA-A receptor, longevity research involving NAD+ metabolism through CD38 inhibition, and cell-biology work on cyclin-dependent kinases. That combination has pushed apigenin from a niche supplement ingredient to a mainstream product category, and dozens of brands now sell it as a standalone capsule.
The trouble is that the supplement market moved faster than the clinical evidence. Most human trials on isolated apigenin are small, short, and industry-adjacent, which means a buyer today has to evaluate products primarily on manufacturing quality rather than brand-sponsored outcome claims. This guide focuses on what actually matters when choosing an apigenin supplement: standardization, third-party testing, excipient safety, dose transparency, and honest labeling—not marketing language.
Key Takeaways
- Apigenin binds the benzodiazepine site of the GABA-A receptor, but in patch-clamp recordings it reduced GABA-evoked currents rather than enhancing them, so the popular “natural benzodiazepine” framing runs backwards. CD38 inhibition and CDK2/CDK6 interactions are separate and better-behaved mechanisms, but human clinical data on isolated oral supplementation remain limited.
- The 50 mg dose ubiquitous in the supplement market comes from popular protocols, not from a clinical trial establishing it as optimal or sufficient for any outcome.
- Apigenin inhibits CYP1A2, CYP2C9 and CYP3A4 in laboratory assays, but whether a 50 mg capsule ever reaches inhibitory concentrations at the liver in a person has not been tested; treat warfarin, statin and benzodiazepine combinations as a question for a pharmacist rather than a documented human interaction.
- Choose products with third-party certification or ISO-accredited CoAs that confirm identity and potency; do not rely on label claims alone.
- Chamomile extract studies provide the most human data in this space, and the one randomised placebo-controlled trial in chronic insomnia found no significant benefit on any sleep diary measure; outcomes from whole-plant extracts should not be directly attributed to isolated apigenin at equivalent doses.
How Apigenin Works: The Proposed Mechanisms
Apigenin does bind the central benzodiazepine site: it competitively displaces flunitrazepam with a Ki near 4 micromolar, while having no effect on binding at the GABA site itself[1]. Binding is not activation, though, and this is where the marketing and the published electrophysiology part company. The phrase partial agonist, borrowed from benzodiazepine pharmacology, is not what the channel recordings show: in recombinant alpha1beta2gamma2 receptors and in cultured cortical neurons, apigenin reversibly reduced GABA-evoked currents and decreased both the amplitude and the frequency of spontaneous inhibitory currents, an antagonist profile rather than a potentiating one[2]. In rats, its sedative effect was not reversed by the benzodiazepine antagonist flumazenil, and apigenin showed no anxiolytic effect at all in that model, while chrysin tested in the same experiment was flumazenil-reversible[3]. The authors of the patch-clamp study concluded that inhibition at the GABA receptor cannot explain what the compound does in a living animal, and proposed a general reduction in network excitability through NMDA-receptor antagonism as the more plausible route to sedation[2]. The anxiolytic effect seen in chamomile extract studies may still owe something to apigenin content, but whole-plant extracts contain dozens of other active compounds, and the mechanism most often printed on the label is the one the recordings do not support.
The NAD+ connection comes through CD38, a cell-surface enzyme that is one of the primary consumers of NAD+ in the body. By modestly inhibiting CD38 activity, apigenin is proposed to preserve NAD+ levels, which decline with age; in the study that characterised this, apigenin raised NAD+ in cultured cells and, given to obese mice, lowered global protein acetylation and improved several measures of glucose and lipid handling[4]. This mechanism is biologically plausible and has generated interest in longevity circles, but human pharmacokinetic data on oral apigenin and its actual effect on tissue NAD+ in people remain limited. The CDK2 and CDK6 inhibition work, which relates to cell-cycle regulation and has been explored in oncology research, is even further from clinical translation and should not be interpreted as evidence that apigenin treats or prevents cancer.
What 'Standardized' Actually Means on an Apigenin Label
Supplements labeled ‘apigenin’ fall into two broad categories: isolated apigenin and chamomile extract standardized to a percentage of apigenin. Isolated apigenin is synthesized or extracted to near-purity, typically sold in 50 mg capsules. Standardized chamomile extract might read ‘500 mg, standardized to 1.2% apigenin,’ delivering around 6 mg of apigenin per capsule alongside the rest of the chamomile matrix. Neither approach is inherently superior, but they are not interchangeable, and dose comparisons between the two are misleading.
When evaluating a standardized extract, the percentage matters less than whether a certificate of analysis (CoA) from an independent laboratory confirms the stated apigenin content. A CoA should report actuals, not just ‘conforms,’ and should come from a lab accredited by ISO 17025 or an equivalent body. For isolated apigenin, the CoA should confirm identity (typically by HPLC with UV detection at 338 nm), purity, and absence of heavy metals and microbial contaminants. If a brand does not publish CoAs or provide them on request, that is a meaningful quality signal.
Dosage: What Is Actually Used in Research vs. What Brands Sell
The most widely sold standalone apigenin dose is 50 mg per capsule, a figure that appears frequently in online longevity protocols. That specific dose became popularized through podcasts rather than through a clinical trial establishing it as optimal. Apigenin has low oral bioavailability, and the human numbers are worse for capsules than most buyers assume. In a controlled study in healthy adults, free apigenin, which is the form sold in isolated-apigenin capsules, was the worst absorbed of the three forms tested: metabolites equal to just 0.5% of intake were recovered in urine over 24 hours, against 11.2% for the apigenin glycoside in parsley and 34% for chamomile tea[5]. Plasma concentrations reached after a specific 50 mg capsule dose are still not published, but the direction is established, and it does not favour the capsule.
Some manufacturers have begun offering apigenin in phospholipid complexes or with piperine, both strategies intended to improve absorption. The phospholipid approach has a reasonable mechanistic rationale for lipophilic polyphenols generally, but apigenin-specific bioavailability data from these formulations in humans are not yet available in peer-reviewed literature. Consumers should treat absorption-enhancement claims as plausible hypotheses rather than confirmed benefits.
Chamomile extract studies, which have the most human data, often use doses delivering a much lower effective apigenin equivalent—sometimes under 10 mg—within a full herbal matrix. Whether isolated apigenin at 50 mg produces the same effects as the chamomile matrix at lower apigenin equivalents is an open question, and the absorption data make it a live one: the smaller apigenin dose in tea was absorbed far more efficiently than the free apigenin in a capsule[5], so a milligram-for-milligram comparison overstates the capsule.
Drug Interactions and Safety Considerations
In laboratory assays, apigenin inhibits cytochrome P450 enzymes including CYP1A2[6], CYP2C9[7][8] and CYP3A4[9]. The CYP2C9 work is the most concrete: apigenin inhibited the metabolism of the blood-pressure drug losartan in human liver microsomes with a half-maximal inhibitory concentration near 4 micromolar, and acted as a competitive inhibitor of the enzyme[7]. These enzymes clear a wide range of pharmaceuticals, including warfarin through CYP2C9 and several statins through CYP3A4, so the theoretical concern is easy to state. What does not exist is a human study: no trial has measured whether a 50 mg oral dose reaches inhibitory concentrations at the liver in a living person. That makes this a good reason to ask a pharmacist before combining apigenin with a prescription, and a poor reason to claim a documented interaction either way.
Apigenin does produce sedation in animals, reducing locomotor activity in rats from 25 mg/kg[3], so stacking it with melatonin, alcohol, antihistamines or prescription benzodiazepines could plausibly add up, and anyone already taking a benzodiazepine should raise it with a physician first. The honest caveat is that the route is unsettled: because the sedation was not reversed by flumazenil[3], it is unlikely to be the benzodiazepine-site effect that supplement labels imply, which also means additivity with benzodiazepines specifically is assumed rather than shown. Pregnant individuals should avoid supplemental doses, though the animal finding is usually misdescribed: in rats given apigenin on days 1 to 4 of pregnancy, the effect was dose-dependent anti-implantation activity, complete at 25 mg/kg, alongside estrogenic changes to the uterus, rather than uterine contraction[10].
There is no established tolerable upper intake level for supplemental apigenin in humans. Food-derived apigenin from a diet rich in parsley or chamomile tea is unlikely to reach pharmacologically relevant concentrations. Concentrated supplements at 50 mg or above represent a meaningfully different exposure level.
What to Look for in a Quality Apigenin Supplement
Third-party certification is the single most useful quality filter available to consumers. NSF Certified for Sport, USP Verified, and Informed Sport are the three most rigorous programs; they test for identity, potency, and contamination including banned substances. Fewer than a handful of apigenin products hold any of these certifications as of 2025. Brands that do not pursue third-party certification but publish CoAs from independent ISO-accredited labs are a reasonable second tier.
Label transparency is the next filter. A trustworthy label states the exact apigenin dose in milligrams, not just the botanical source or a proprietary blend weight. It discloses all excipients. It names the manufacturing facility and whether it is NSF GMP registered or FDA-registered. Claims on the label should be structure-function claims, not disease claims; if a label says the product ‘supports healthy sleep’ that is compliant language, if it says it ‘treats insomnia’ that is not.
Packaging matters for a compound that degrades on exposure to light and moisture. Dark glass or opaque HDPE bottles with desiccant are preferable to clear plastic. Some brands seal individual capsule blisters, which meaningfully extends stability. These details are not cosmetic; polyphenols are oxidation-sensitive, and a product that sat in a clear plastic bottle on a warm warehouse shelf for six months before shipping may not deliver what the label states.
Honest Assessment of the Evidence Gap
It would be misleading to rank apigenin supplements by clinical outcome because the human clinical evidence for isolated oral apigenin is sparse. The mechanisms are scientifically plausible and the preclinical data are substantial, but plausible mechanisms do not guarantee efficacy at a given oral dose in people. The sleep and anxiety data that exist come predominantly from chamomile extract studies, not from isolated apigenin trials, and extrapolating from whole-plant extract studies to isolated compounds has a poor track record in nutritional science. It is worth being concrete about what those studies found. The one randomised, double-blind, placebo-controlled trial in chronic primary insomnia gave 34 adults 270 mg of standardised chamomile twice daily for 28 days and found no significant difference from placebo on any sleep diary measure, including total sleep time, sleep latency, sleep efficiency and night-time awakenings[11]. No trial has tested isolated apigenin at 50 mg for sleep at all.
The CD38 and NAD+ mechanism is genuinely interesting and has a defensible biological rationale, but the human evidence connecting oral apigenin supplementation to meaningful changes in NAD+ status, let alone to longevity outcomes, does not exist yet. Consumers who are taking apigenin primarily for this reason are making a speculative bet on a mechanistic pathway, not acting on clinical proof of benefit. That bet may be reasonable given low known risk at typical doses for healthy adults without drug interactions, but it should be understood as such.
🛒 Where to Buy Apigenin
- Momentous ApigeninLab-tested / studied
capsules, 50 mg per capsule, 60 count — The only NSF Certified for Sport option here, meaning batch testing against a banned-substance list and verification that the label matches the contents - Vitamatic Apigenin 50mg
capsules, 50 mg per capsule, 120 vegetarian capsules — The lowest cost per dose on this list, and a vegetarian capsule if gelatin is a constraint; the listing states no third-party certification - Nutricost Apigenin 50mg
capsules, 50 mg per capsule, 180 count — Non-GMO, gluten free and vegan, and the best cost per capsule among the larger bottles here - Swanson Apigenin 50mg
capsules, 50 mg per capsule, 90 count — A long-established supplement brand, in the smaller 90-count bottle; the listing frames it around sleep and relaxation
As an Amazon Associate we earn from qualifying purchases. Apigenin products differ mainly in what else is in the capsule — some are plain apigenin, others blend it with L-theanine, valerian root or magnesium — so check the label for the actual apigenin dose per serving, and prefer products that publish third-party testing.
A Note on the Evidence
The evidence base for isolated oral apigenin in humans is early and limited; most mechanistic claims rest on cell and animal studies rather than clinical trials. These statements have not been evaluated by the FDA, and apigenin is not intended to diagnose, treat, cure, or prevent any disease. Individuals on warfarin, statins, or benzodiazepines should consult a physician before use; this article is informational only and does not constitute medical advice.
Frequently Asked Questions
What is the best dose of apigenin for sleep?
There is no established optimal dose for isolated apigenin and sleep in humans. Most commercial products use 50 mg, a figure popularized through longevity podcasts rather than clinical trial results. Chamomile extract products have more human trial data behind them, but that data is not encouraging: the one randomised, double-blind, placebo-controlled trial in chronic primary insomnia gave 34 adults 270 mg of standardised chamomile twice daily for 28 days and found no significant difference from placebo on any sleep diary measure. No trial has tested isolated apigenin at 50 mg for sleep at all.
Can I take apigenin with melatonin?
Combining apigenin with melatonin may add to sedation, but the mechanism behind apigenin’s sedative effect is unsettled: in rats it was not reversed by the benzodiazepine antagonist flumazenil, which argues against the GABA-benzodiazepine route that supplement marketing assumes. This combination is not proven dangerous at typical consumer doses, but individuals who are sensitive to sedation or who drive or operate machinery should use caution. Starting with lower doses of each and assessing tolerance individually before combining is a prudent approach.
Does apigenin actually raise NAD+ levels?
Apigenin inhibits CD38, an enzyme that consumes NAD+, which is a biologically plausible mechanism for supporting NAD+ availability. However, human evidence directly measuring NAD+ changes after oral apigenin supplementation is not yet available in published peer-reviewed literature. The mechanism is real at a cellular level; whether an oral supplement dose produces meaningful NAD+ changes in tissue in living people has not been confirmed.
Is apigenin safe for long-term use?
There is no established tolerable upper intake level for supplemental apigenin in humans, and long-term safety data from controlled trials do not exist. Apigenin from food sources—chamomile tea, parsley, celery—has a long history of safe consumption at dietary levels. Concentrated supplements represent a higher exposure than typical dietary intake, and the long-term risk profile at those levels is not well characterized. Anyone with a chronic health condition or on prescription medications should consult a physician before sustained use.
What is the difference between apigenin and chamomile extract?
Chamomile extract is a whole-plant extract that contains apigenin alongside many other flavonoids, terpenoids, and phenolic acids. Isolated apigenin is a single purified compound. The two are not interchangeable: effects observed in chamomile extract studies may reflect the whole matrix rather than apigenin alone, and a dose of isolated apigenin that matches the apigenin content of a chamomile dose may not replicate the same effects.
Who should not take apigenin supplements?
Individuals taking warfarin, certain statins, or benzodiazepines should consult a physician before use due to CYP enzyme inhibition that can alter drug metabolism. Pregnant individuals should avoid supplemental doses: in rats given apigenin on days 1 to 4 of pregnancy, it produced dose-dependent anti-implantation activity, complete at 25 mg/kg, together with estrogenic changes to the uterus. Anyone with a known allergy to plants in the Asteraceae family, which includes chamomile, should be cautious with chamomile-derived products specifically.
References
- Viola H et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med (1995). PMID 7617761
- Losi G et al. Apigenin modulates GABAergic and glutamatergic transmission in cultured cortical neurons. Eur J Pharmacol (2004). PMID 15464088
- Zanoli P et al. Behavioral characterisation of the flavonoids apigenin and chrysin. Fitoterapia (2000). PMID 10930722
- Escande C et al. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes (2013). PMID 23172919
- Borges G et al. Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free Radic Biol Med (2022). PMID 35452808
- Shimada H et al. Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein. J Biochem Mol Toxicol (2010). PMID 20806393
- Wang Z et al. Inhibitory effect of apigenin on losartan metabolism and CYP2C9 activity in vitro. Pharmacology (2016). PMID 27287328
- Si D et al. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos (2009). PMID 19074529
- Kondza M et al. Characterization of the CYP3A4 enzyme inhibition potential of selected flavonoids. Molecules (2021). PMID 34069400
- Hiremath SP et al. Antifertility and hormonal properties of flavones of Striga orobanchioides. Eur J Pharmacol (2000). PMID 10720651
- Zick SM et al. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complement Altern Med (2011). PMID 21939549
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
